WNY Asset Management LLC Takes Position in Pfizer Inc. $PFE

WNY Asset Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 33,878 shares of the biopharmaceutical company’s stock, valued at approximately $951,000.

Other large investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. YANKCOM Partnership acquired a new stake in Pfizer in the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC lifted its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its position in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $31,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.10 on Friday. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a market cap of $143.06 billion, a P/E ratio of 19.16 and a beta of 0.35. The business’s 50 day moving average is $25.04 and its two-hundred day moving average is $26.15. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Guggenheim dropped their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Citigroup raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Morgan Stanley lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.50.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.